CD8A and non-small cell lung carcinoma: Accordingly, changes in the frequency of CD8+ T cells among PB CD3+ T cells did not correlate with OS and PFS in all NSCLC patients (Supplementary Fig. 10b) and NSCLC patients who had a PD-L1 TPS of at least 50% and were treated with pembrolizumab (Supplementary Fig. 10c).